Top 5 Small-cap Pharma Stocks (Updated January 2026)
2026-01-05 16:15:00 ET
Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval.
However, the industry's major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected to dissipate.
The US reigns supreme in the pharma market, both in terms of drug demand and development. In 2025, 46 novel medicines were approved by the US Food and Drug Administration (FDA), compared to 50 such approvals in 2024.
Big pharma largely steals the show when people discuss pharmaceutical companies, but some small- and mid-cap NASDAQ pharma stocks have also made gains.
For further details see:
Top 5 Small-cap Pharma Stocks (Updated January 2026)
NASDAQ: DERM
DERM Trading
-1.2% G/L:
$7.80 Last:
21,393 Volume:
$7.72 Open:
